Results 141 to 150 of about 62,277 (245)

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract There are currently no approved pharmacotherapies to treat cognitive impairment associated with schizophrenia (CIAS). Iclepertin (BI 425809) is a selective glycine transporter‐1 (GlyT1) inhibitor that was investigated for the treatment of CIAS.
Peter Nagy, Justin Corey Fowler, Holger Rosenbrock, Wenbo Tang, Eric Fu, Annie Fraser, Holly Dursema, Julia Schlichtiger, Michael Desch, Fredrik Gruenenfelder   +9 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Subclinical hypomania, psychiatric and neurodevelopmental diagnoses: phenotypic and aetiological overlap

Journal of Child Psychology and Psychiatry, Volume 67, Issue 5, Page 686-695, May 2026.
Background Subclinical hypomanic symptoms are fairly common in the general population but are linked to psychiatric and neurodevelopmental conditions. However, the genetic and environmental origins of these associations are unclear. This twin study examined the phenotypic and aetiological associations between subclinical hypomania and psychiatric and ...
Georgina M. Hosang, Miriam I. Martini, Angelica Ronald, Henrik Larsson, Sebastian Lundström, Paul Lichtenstein, Mark J. Taylor   +6 more
wiley   +1 more source

Antipsychotic treatment in schizophrenia: balancing relapse prevention and functional recovery

Schizophrenia
Jan P. A. M. Bogers
doaj   +1 more source

Clozapine prescribing in treatment-resistant schizophrenia - an updated systematic literature review of barriers and facilitators among clinicians. [PDF]

Eur J Clin Pharmacol
Nolan S, Sahm LJ, Fitzgerald I.
europepmc   +1 more source

Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system. [PDF]

Ther Adv Psychopharmacol
Kang N, Jang JS, Joo SW, Lee JH, Jeong JH, Kim M, Ahn YM, Kwon JS, Kim YS, Lee JS, Kim SH.   +10 more
europepmc   +1 more source

Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. [PDF]

, 2020
Do, Thao P, Giacomini, Kathleen M, Huang, Shiew-Mei, Krauss, Ronald M, Kusuhara, Hiroyuki, Sugiyama, Yuichi, Unadkat, Jashvant D, Yee, Sook Wah   +7 more
core   +2 more sources

A Case of Clozapine Toxicity Caused by Infection in a Patient with Treatment-Resistant Schizophrenia. [PDF]

Int Med Case Rep J
Tomita T, Ozawa S, Akasaka K, Nakamura K.   +3 more
europepmc   +1 more source

Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank, Sharon-Lise Normand, Thomas G. McGuire   +2 more
core  

Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response. [PDF]

Ther Adv Psychopharmacol
Dang VM, Powers JM, Markota M, Leung JG.
europepmc   +1 more source